15 September 2025 — PrimaNova Technologies has successfully completed the first closing of its Series B financing round, led by JAFCO Asia. The funds raised will accelerate the development of multiple neurosurgical medical devices in the pipeline, and bolster the commercialization of PrimaNova’s Neurointensive Monitoring System that was recently approved by the China National Medical Products Administration (“NMPA”).

The company also announced the official launch of the Neurointensive Monitoring System during the 22nd Academic Conference of the Neurosurgery Branch of the Chinese Medical Association (“CNS2025”) in August 2025. The product launch event was honored by the presence of leading clinical experts, including Professor Jiyao Jiang, Chief Specialist at Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine; Professor Wai Sang Poon, Consultant at the Neuromedicine Center of The University of Hong Kong-Shenzhen Hospital; and Director Zhang Wangming from the Neurosurgery Center of Zhujiang Hospital, Southern Medical University.

**Product Launch Event of PrimaNova’s Neurointensive Monitoring System

Following the first closing, JAFCO Asia will appoint a representative to join the Board of Directors alongside the company’s Vice President, Mr. Steven Tang. At the same time, current Non-Executive Directors Dr. Daniel Burnett and Dr. Mingxi Li will step down from the Board.

PrimaNova’s Chief Technology Officer Dr Ping Wen stated, “The Neurointensive Monitoring System features an innovative wireless connection design that significantly reduces risks associated with traditional catheters, such as infection, probe displacement, and cerebrospinal fluid leakage. This breakthrough overcomes the limitations of conventional monitoring by enabling real-time, continuous, and multimodal monitoring. Moreover, leveraging our proprietary sensors and advanced signal processing technologies, we have greatly enhanced monitoring accuracy and stability, providing robust clinical support at the bedside.”

PrimaNova’s President Sampson Lau expressed gratitude, stated, “We sincerely thank our dedicated team and investors for their trust and support, which have enabled PrimaNova to reach this pivotal milestone. We especially appreciate JAFCO Asia’s involvement, which brings powerful momentum to our commercialization efforts. Looking ahead, we will continue to innovate and launch next-generation products to promote technological advancement and clinical applications in neurosurgery, benefiting more patients, globally.”

PrimaNova’s Neurointensive Monitoring System

About PrimaNova Technologies At PrimaNova®, we are revolutionizing neurosurgery with innovative solutions that transform patient care. By combining advanced technologies with a deep understanding of neurological complexities, we empower neurosurgeons to tackle even the most challenging cases with confidence. Our goal is to fundamentally change treatment paradigms and redefine the standard of care, with patients and clinicians at heart.

About JAFCO Asia JAFCO Asia is a leading brand in the venture capital industry in the Asia Pacific. It was established since 1990 and has offices in Singapore, Beijing, Shanghai, Taipei. With more than US$480 million funds under management currently (US$1.88 billion funds cumulative to-date), JAFCO Asia has invested in more than 500 companies, of which at least 115 have been publicly listed.